USD 2.2999
↑ 0.0699 (3.13%)
| ticker | 1 day return % | 1 week return % | 1 month return % | 3 months return % | 6 months return % | 1 year return % | 3 years return % | 5 years return % | 10 years return % | maximum return % |
|---|---|---|---|---|---|---|---|---|---|---|
| PHIO | 3.1 | -31.3 | -16.7 | -10.9 | -68.1 | -75.4 | -98.6 | -99.8 | -100.0 | -99.9 |
| S&P 500 | -1.1 | -1.5 | 1.2 | 6.2 | 10.9 | 30.7 | 25.7 | 88.6 | 188.3 | 33220.8 |
Our interactive price chart includes various drawing tools to help you analyze the product more effectively. Below is a quick guide on how to use these tools: Full Guideline
Feel free to experiment with these tools to enhance your technical analysis. Remember, any drawings you make are temporary and will be lost upon refreshing the page unless saved as an image using the 'Camera' icon.
Get instant AI-powered professional insights on prices:
💡Generate AI Technical Analysis ReportA Multi-Interval Candlestick Chart displays the price movements of an asset over different time intervals. Each candlestick represents the open, high, low, and close prices for a specific interval. The chart can be used to identify trends and patterns in price movements.
| Attribute | Value |
|---|---|
| symbol | PHIO |
| name | Phio Pharmaceuticals Corp. |
| price | 2.30 |
| changes percentage | 3.13 |
| change | 0.07 |
| day low | 2.29 |
| day high | 2.45 |
| year high | 18.81 |
| year low | 2.21 |
| market cap | 1979572 |
| price avg 50 | 3.06 |
| price avg 200 | 5.16 |
| exchange | NASDAQ |
| volume | 9197 |
| avg volume | 63356 |
| open | 2.45 |
| previous close | 2.23 |
| eps | -16.13 |
| pe | -0.14 |
| earnings announcement | 2024-11-15T12:00:00.000+0000 |
| shares outstanding | 860721 |
| timestamp | 2024-11-15 15:25:01 |
We derive the score of a company's financial statements by evaluating the weighted average sentiment across key within the statements. The cumulative score, normalized to a sum of 1, serves as a metric for assessing the company's performance during the specified period. A higher score indicates stronger performance. However, it's crucial to note that while this score provides valuable insights, it is just one of many factors to consider when making informed investment decisions. A holistic evaluation, considering various aspects of the company's financial health and market conditions, is essential for a well-rounded investment strategy.
| 2023 | 2022 | Y/Y change % | |
|---|---|---|---|
| 0001533040 | |||
| revenue | 0 | 0 | NaN |
| gross profit | -6332000 | -193000 | -3,180.83 |
| gross profit ratio | 0 | 0 | NaN |
| research and development expenses | 6332000 | 7012000 | -9.70 |
| operating expenses | 4492000 | 11462000 | -60.81 |
| interest income | 0 | 0 | NaN |
| interest expense | 0 | -175000 | 100.00 |
| ebitda | -10642000 | -11287000 | 5.71 |
| ebitdaratio | 0 | 0 | NaN |
| operating income | -10824000 | -11462000 | 5.57 |
| operating income ratio | 0 | 0 | NaN |
| net income | -10826000 | -11305000 | 4.24 |
| net income ratio | 0 | 0 | NaN |
| eps | -46.87 | -9.95 | -371.06 |
Gross Profit: Gross Profit decreased to -6 million in 2023 from 0 million in 2022 representing a change of -3180.83%. This indicates a sales profitability decline, which is a negative sign for the company.
Research and Development (R&D) Expenses: R&D Expenses decreased to 6 million in 2023 from 7 million in 2022 representing a change of -9.7%. This shows that the company decreased investment in innovation and product development, which is not a good sign for long-term growth.
Operating Expenses: Operating Expenses increased to 4 million in 2023 from 11 million in 2022 representing a change of -60.81%. The increase in operating expenses can be attributed to various factors such as marketing, administrative costs, and investments in infrastructure. It's important to monitor if these expenses are growing at a sustainable rate compared to revenue.
EBITDA: EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) decreased to -11 million in 2023 from -11 million in 2022 representing a change of 5.71%. The decrease in EBITDA indicates declined operational efficiency and profitability.
Operating Income: Operating income decreased to -11 million in 2023 from -11 million in 2022 representing a change of 5.57%. The decrease in operating income indicates worse operational performance and decreased profitability.
Net Income: Net income decreased to -11 million in 2023 from -11 million in 2022 representing a change of 4.24%. The decrease in net income shows worsen profitability and indicates that the company is generating less profit for each dollar of revenue.
Earnings per Share (EPS): EPS increased to -46.87 in 2023 from -46.87 in 2022 representing a change of -371.06%. This indicates that the company's earnings are decreasing and it is becoming less profitable on a per-share basis.
| 2024Q3 | 2024Q2 | Q/Q change % | |
|---|---|---|---|
| 0001533040 | |||
| revenue | 0 | 0 | NaN |
| gross profit | 0 | -1000 | 100.00 |
| gross profit ratio | 0 | 0 | NaN |
| research and development expenses | 644000 | 866000 | -25.64 |
| operating expenses | 1590000 | 1914000 | -16.93 |
| interest income | 0 | 0 | NaN |
| interest expense | 0 | 0 | NaN |
| ebitda | 0 | -1845000 | 100.00 |
| ebitdaratio | 0 | 0 | NaN |
| operating income | 0 | -1914000 | 100.00 |
| operating income ratio | 0 | 0 | NaN |
| net income | -1524000 | -1846000 | 17.44 |
| net income ratio | 0 | 0 | NaN |
| eps | -0.0 | -3.62 | 99.96 |
Gross Profit: Gross Profit increased to 0 million in 2024Q3 from 0 million in 2024Q2 representing a change of 100.0%. This indicates a sales profitability growth, which is a positive sign for the company.
Operating Expenses: Operating Expenses decreased to 2 million in 2024Q3 from 2 million in 2024Q2 representing a change of -16.93%. The decrease in operating expenses can be attributed to various factors such as improved profitability, cost optimization and financial stability, lower operating expenses can be positive indicators.
EBITDA: EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) increased to 0 million in 2024Q3 from -2 million in 2024Q2 representing a change of 100.0%. The increase in EBITDA indicates improved operational efficiency and profitability.
Operating Income: Operating income increased to 0 million in 2024Q3 from -2 million in 2024Q2 representing a change of 100.0%. The increase in operating income indicates better operational performance and increased profitability.
Earnings per Share (EPS): EPS increased to -0.0 in 2024Q3 from -0.0 in 2024Q2 representing a change of 99.96%. This indicates that the company's earnings are increasing and it is becoming more profitable on a per-share basis.
Research and Development (R&D) Expenses: R&D Expenses decreased to 1 million in 2024Q3 from 1 million in 2024Q2 representing a change of -25.64%. This shows that the company decreased investment in innovation and product development, which is not a good sign for long-term growth.
Net Income: Net income decreased to -2 million in 2024Q3 from -2 million in 2024Q2 representing a change of 17.44%. The decrease in net income shows worsen profitability and indicates that the company is generating less profit for each dollar of revenue.
| 2023 | 2022 | Y/Y change % | |
|---|---|---|---|
| 0001533040 | |||
| total assets | 9364000 | 12814000 | -26.92 |
| total liabilities | 1634000 | 1976000 | -17.31 |
| total equity | 7730000 | 10838000 | -28.68 |
| cash and cash equivalents | 8490000 | 11781000 | -27.93 |
| short term investments | 0 | 0 | NaN |
| long term investments | 0 | 0 | NaN |
| total current assets | 9322000 | 12446000 | -25.10 |
| total non current assets | 42000 | 368000 | -88.59 |
| total current liabilities | 1634000 | 1804000 | -9.42 |
| total non current liabilities | 0 | 172000 | -100.00 |
| common stock | 0 | 0 | NaN |
| retained earnings | -139206000 | -128380000 | -8.43 |
| total debt | 35000 | 305000 | -88.52 |
Total Assets: Total Assets decreased to 9 million in 2023 from 13 million in 2022 representing a change of -26.92%. Suggesting a decrease in asset holdings.
Total Equity: Total Equity decreased to 8 million in 2023 from 11 million in 2022 representing a change of -28.68%. This indicates a decrease in shareholders' equity.
Cash And Cash Equivalents: Cash And Cash Equivalents decreased to 8 million in 2023 from 12 million in 2022 representing a change of -27.93%. This indicates a decrease in available liquid assets.
Total Current Assets: Total Current Assets decreased to 9 million in 2023 from 12 million in 2022 representing a change of -25.1%. This indicates a worsen liquidity position.
Retained Earnings: Retained Earnings decreased to -139 million in 2023 from -128 million in 2022 representing a change of -8.43%. This indicates an accumulated losses.
Total Liabilities: Total Liabilities decreased to 2 million in 2023 from 2 million in 2022 representing a change of -17.31%. This indicates a decrease in overall liabilities.
Total Current Liabilities: Total Current Liabilities decreased to 2 million in 2023 from 2 million in 2022 representing a change of -9.42%. This indicates a lower short-term debt burden.
Total Debt: Total Debt decreased to 0 million in 2023 from 0 million in 2022 representing a change of -88.52%. This indicates a reduction in overall debt burden.
| 2024Q3 | 2024Q2 | Q/Q change % | |
|---|---|---|---|
| 0001533040 | |||
| total assets | 5865000 | 5296000 | 10.74 |
| total liabilities | 919000 | 1523000 | -39.66 |
| total equity | 4946000 | 3773000 | 31.09 |
| cash and cash equivalents | 5390000 | 4698000 | 14.73 |
| short term investments | 0 | 0 | NaN |
| long term investments | 0 | 0 | NaN |
| total current assets | 5864000 | 5292000 | 10.81 |
| total non current assets | 1000 | 4000 | -75.00 |
| total current liabilities | 919000 | 1523000 | -39.66 |
| total non current liabilities | 0 | 0 | NaN |
| common stock | 0 | 0 | NaN |
| retained earnings | -144730000 | -143206000 | -1.06 |
| total debt | 0 | 0 | NaN |
Total Assets: Total Assets increased to 6 million in 2024Q3 from 5 million in 2024Q2 representing a change of 10.74%. Suggesting a growth in asset holdings.
Total Liabilities: Total Liabilities decreased to 1 million in 2024Q3 from 2 million in 2024Q2 representing a change of -39.66%. This indicates a decrease in overall liabilities.
Total Equity: Total Equity increased to 5 million in 2024Q3 from 4 million in 2024Q2 representing a change of 31.09%. This indicates an increase in shareholders' equity.
Cash And Cash Equivalents: Cash And Cash Equivalents increased to 5 million in 2024Q3 from 5 million in 2024Q2 representing a change of 14.73%. This indicates an increase in available liquid assets.
Total Current Assets: Total Current Assets increased to 6 million in 2024Q3 from 5 million in 2024Q2 representing a change of 10.81%. This indicates a better liquidity position.
Total Current Liabilities: Total Current Liabilities decreased to 1 million in 2024Q3 from 2 million in 2024Q2 representing a change of -39.66%. This indicates a lower short-term debt burden.
Retained Earnings: Retained Earnings decreased to -145 million in 2024Q3 from -143 million in 2024Q2 representing a change of -1.06%. This indicates an accumulated losses.
| 2023 | 2022 | Y/Y change % | |
|---|---|---|---|
| 0001533040 | |||
| net change in cash | -3341000 | -12276000 | 72.78 |
| operating cash flow | -10749000 | -12129000 | 11.38 |
| free cash flow | -10754000 | -12250000 | 12.21 |
| capital expenditure | -5000 | -121000 | 95.87 |
| depreciation and amortization | 184000 | 193000 | -4.66 |
| deferred income tax | 0 | -304000 | 100.00 |
| stock based compensation | 303000 | 414000 | -26.81 |
| accounts payables | -122000 | 496000 | -124.60 |
| inventory | 0 | 0 | NaN |
| acquisitions net | 0 | 0 | NaN |
| investments in property plant and equipment | -5000 | -121000 | 95.87 |
| net cash used for investing activites | -5000 | -121000 | 95.87 |
| debt repayment | 0 | 0 | NaN |
| common stock issued | 7452000 | 2000 | 372,500.00 |
| common stock repurchased | -13000 | -28 | -46,328.57 |
| dividends paid | 0 | 0 | NaN |
| net cash used provided by financing activities | 7413000 | -26000 | 28,611.54 |
| cash at end of period | 8490000 | 11831000 | -28.24 |
| accounts receivables | 0 | 0 | NaN |
| cash at beginning of period | 11831000 | 24107000 | -50.92 |
Net Change in Cash: Net Change in Cash increased to -3 million in 2023 from -12 million in 2022 representing a change of 72.78%. Indicating an increased ability to generate cash from the company's operations or its cash flow position.
Operating Cash Flow: Operating Cash Flow increased to -11 million in 2023 from -12 million in 2022 representing a change of 11.38%. This indicates that the company generated more cash from its core business operations.
Free Cash Flow: Free Cash Flow increased to -11 million in 2023 from -12 million in 2022 representing a change of 12.21%. This indicates an increase in cash generated after accounting for capital expenditures.
Stock-Based Compensation: Stock-Based Compensation decreased to 0 million in 2023 from 0 million in 2022 representing a change of -26.81%. This indicates decreased expenses, which is generally considered a positive sign from a financial perspective.
Accounts Payables: The absolute value of Accounts Payables decreased to 0 million in 2023 from 0 million in 2022 representing a change of -124.6%. This indicates that the company has reduced its outstanding obligations to its suppliers.
Capital Expenditure: Capital Expenditure increased to 0 million in 2023 from 0 million in 2022 representing a change of 95.87%. This indicates an increase in the cash outflow required for acquiring or improving long-term assets.
Deferred Income Tax: Deferred Income Tax increased to 0 million in 2023 from 0 million in 2022 representing a change of 100.0%. This indicates that the company's tax liability for future periods has increased.
| 2024Q3 | 2024Q2 | Q/Q change % | |
|---|---|---|---|
| 0001533040 | |||
| operating cash flow | -1360000 | -1777000 | 23.47 |
| free cash flow | -1360000 | -1777000 | 23.47 |
| capital expenditure | 0 | 0 | NaN |
| depreciation and amortization | -42000 | 1000 | -4,300.00 |
| deferred income tax | 0 | 0 | NaN |
| stock based compensation | 58000 | 15000 | 286.67 |
| accounts receivables | 0 | 0 | NaN |
| accounts payables | -620000 | 15000 | -4,233.33 |
| inventory | 0 | 0 | NaN |
| acquisitions net | 0 | 0 | NaN |
| investments in property plant and equipment | 0 | 0 | NaN |
| net cash used for investing activites | 0 | 0 | NaN |
| debt repayment | 0 | 0 | NaN |
| common stock issued | 242000 | 0 | NaN |
| common stock repurchased | 0 | 0 | NaN |
| dividends paid | 0 | 0 | NaN |
| net cash used provided by financing activities | 242000 | 0 | NaN |
| net change in cash | -1085000 | -1777000 | 38.94 |
| cash at end of period | 5390000 | 4698000 | 14.73 |
| cash at beginning of period | 6475000 | 6475000 | 0.00 |
Net Change in Cash: Net Change in Cash increased to -1 million in 2024Q3 from -2 million in 2024Q2 representing a change of 38.94%. Indicating an increased ability to generate cash from the company's operations or its cash flow position.
Operating Cash Flow: Operating Cash Flow increased to -1 million in 2024Q3 from -2 million in 2024Q2 representing a change of 23.47%. This indicates that the company generated more cash from its core business operations.
Free Cash Flow: Free Cash Flow increased to -1 million in 2024Q3 from -2 million in 2024Q2 representing a change of 23.47%. This indicates an increase in cash generated after accounting for capital expenditures.
Stock-Based Compensation: Stock-Based Compensation increased to 0 million in 2024Q3 from 0 million in 2024Q2 representing a change of 286.67%. This indicates increased expenses, which is generally considered a negative sign from a financial perspective.
Accounts Payables: The absolute value of Accounts Payables increased to 1 million in 2024Q3 from 0 million in 2024Q2 representing a change of -4233.33%. This indicates that the company has increased its outstanding obligations to its suppliers.
We save you time by utilizing Generative AI to summarize earnings transcripts. Our summaries provide a clear insight into the company's current performance, future outlook, and overall sentiment expressed during the call. Click on below links to explore more.
Note: The years mentioned below are fiscal years in accounting.
Q3 2018 Earnings call transcript
EPS represents the portion of a company's profit allocated to each outstanding share of common stock. A higher EPS is generally favorable, indicating stronger profitability on a per-share basis.
Positive EPS: A positive EPS signifies that a company is profitable, it is generally viewed positively, supporting stock value and investor confidence.
Negative EPS: Indicates that a company is operating at a loss, which could lead to negative sentiment, potential stock depreciation, and concerns about the company's financial health.
The Next Earning Date represents when the company plans to release its next set of financial results.
An upward trend in EPS suggests consistent growth in earnings, often leading to increased investor confidence. A downward trend may indicate a decline in earnings, potentially decreasing investor confidence and stock value. Fluctuating EPS suggests unpredictable financial performance, warranting cautious investor analysis.
Earnings surprise occurs when a company's actual earnings differ from analysts' expectations. A positive earnings surprise typically reflects better-than-expected performance, potentially leading to stock appreciation. Conversely, a negative earnings surprise can result in stock depreciation. An earnings surprise of zero means the earnings met expectations, which typically has a neutral impact on stock price.
Discover detailed analyst recommendations for stocks, including categories such as Buy, Hold, Sell, Strong Buy, and Strong Sell. These insights are based on thorough analysis of financial and market factors. The consensus is calculated by assigning a numerical score to each recommendation. These scores are then weighted and averaged over a specified period to provide a comprehensive view of the stock's outlook, with the final score determining the overall consensus.
| 2023-12-31 | 2022-12-31 | Y/Y change % | |
|---|---|---|---|
| FY | |||
| calendar year | 2023 | 2022 | NaN |
| revenue per share | 0 | 0 | NaN |
| net income per share | -46.87 | -9.95 | -371.17 |
| operating cash flow per share | -46.53 | -10.67 | -336.04 |
| free cash flow per share | -46.55 | -10.78 | -331.93 |
| cash per share | 36.75 | 10.37 | 254.58 |
| book value per share | 33.46 | 9.54 | 250.93 |
| tangible book value per share | 33.46 | 9.54 | 250.93 |
| shareholders equity per share | 33.46 | 9.54 | 250.93 |
| interest debt per share | 0.15 | -0.04 | 530.52 |
| market cap | 1580040 | 45667382.6 | -96.54 |
| enterprise value | -6874960 | 34191382.6 | -120.11 |
| pe ratio | -0.15 | -4.04 | 96.39 |
| price to sales ratio | 0 | 0 | NaN |
| pocfratio | -0.15 | -3.77 | 96.10 |
| pfcf ratio | -0.15 | -3.73 | 96.06 |
| pb ratio | 0.2 | 4.21 | -95.15 |
| ptb ratio | 0.2 | 4.21 | -95.15 |
| ev to sales | 0 | 0 | NaN |
| enterprise value over ebitda | 0.65 | -3.03 | 121.33 |
| ev to operating cash flow | 0.64 | -2.82 | 122.69 |
| ev to free cash flow | 0.64 | -2.79 | 122.90 |
| earnings yield | -6.85 | -0.25 | -2,667.81 |
| free cash flow yield | -6.81 | -0.27 | -2,437.30 |
| debt to equity | 0.0 | 0.01 | -63.65 |
| debt to assets | 0.0 | 0.01 | -64.52 |
| net debt to ebitda | 0.79 | 1.02 | -21.86 |
| current ratio | 5.71 | 6.9 | -17.31 |
| interest coverage | 0 | 65.5 | -100.00 |
| income quality | 0.99 | 1.06 | -6.02 |
| dividend yield | 0 | 0 | NaN |
| payout ratio | 0 | 0 | NaN |
| sales general and administrative to revenue | 0 | 0 | NaN |
| research and ddevelopement to revenue | 0 | 0 | NaN |
| intangibles to total assets | 0 | 0 | NaN |
| capex to operating cash flow | -0.0 | -0.01 | 95.34 |
| capex to revenue | 0 | 0 | NaN |
| capex to depreciation | 0.03 | 0.63 | -95.67 |
| stock based compensation to revenue | 0 | 0 | NaN |
| graham number | 187.85 | 46.2 | 306.63 |
| roic | -1.39 | -1.03 | -35.51 |
| return on tangible assets | -1.16 | -0.88 | -31.05 |
| graham net net | 29.68 | 8.63 | 244.04 |
| working capital | 7688000 | 10642000 | -27.76 |
| tangible asset value | 7730000 | 10838000 | -28.68 |
| net current asset value | 7688000 | 10470000 | -26.57 |
| invested capital | 7727000 | 10986000 | -29.67 |
| average receivables | 0 | 0 | NaN |
| average payables | 718000 | 531000 | 35.22 |
| average inventory | 0 | 0 | NaN |
| days sales outstanding | 0 | 0 | NaN |
| days payables outstanding | 37.87 | 1473.24 | -97.43 |
| days of inventory on hand | 0 | 0 | NaN |
| receivables turnover | 0 | 0 | NaN |
| payables turnover | 9.64 | 0.25 | 3,790.05 |
| inventory turnover | 0 | 0 | NaN |
| roe | -1.4 | -1.04 | -34.27 |
| capex per share | 0.02 | 0.11 | -79.67 |
ROE: Return on Equity (ROE) decreased to -1.40 on 2023-12-31 from -1.04 on 2022-12-31, representing a change of -34.27%. Suggesting that the company has not been generating high returns for its shareholders.
Current Ratio: Current Ratio decreased to 5.71 on 2023-12-31 from 6.90 on 2022-12-31, representing a change of -17.31%. The current ratio has been declining, suggesting a decrease in the company's short-term liquidity. Since it's above 3, indicating poor management of working capital.
PE Ratio: Price-to-Earnings (P/E) Ratio increased to -0.15 on 2023-12-31 from -4.04 on 2022-12-31, representing a change of 96.39%. Indicating an increase in the relative valuation of the company's stock.
Debt-to-Equity Ratio: Debt-to-Equity Ratio decreased to 0.00 on 2023-12-31 from 0.01 on 2022-12-31, representing a change of -63.65%. The debt-to-equity ratio has been decreasing, indicating that the company has been relying less on debt financing. A ratio of 1 or below is often considered healthy and indicates that the company's total debt is equal to or less than its total equity.
| 2024-09-30 Q3 | 2024-06-30 Q2 | Q/Q change % | |
|---|---|---|---|
| PHIO | |||
| calendar year | 2024 | 2024 | NaN |
| revenue per share | 0 | 0 | NaN |
| net income per share | -0.0 | -3.62 | 99.96 |
| operating cash flow per share | -0.0 | -3.48 | 99.96 |
| free cash flow per share | -0.0 | -3.48 | 99.96 |
| cash per share | 0.01 | 9.21 | -99.94 |
| book value per share | 0.0 | 7.4 | -99.93 |
| tangible book value per share | 0.0 | 7.4 | -99.93 |
| shareholders equity per share | 0.0 | 7.4 | -99.93 |
| interest debt per share | 0 | 0 | NaN |
| market cap | 3415613850 | 3086637.4 | 110,558.09 |
| enterprise value | 3410223850 | -1611362.6 | 211,736.03 |
| pe ratio | -560.3 | -0.42 | -133,938.60 |
| price to sales ratio | 0 | 0 | NaN |
| pocfratio | -2511.48 | -1.74 | -144,487.81 |
| pfcf ratio | -2511.48 | -1.74 | -144,487.81 |
| pb ratio | 690.58 | 0.82 | 84,314.27 |
| ptb ratio | 690.58 | 0.82 | 84,314.27 |
| ev to sales | 0 | 0 | NaN |
| enterprise value over ebitda | 0 | 0.87 | -100.00 |
| ev to operating cash flow | -2507.52 | 0.91 | -276,627.37 |
| ev to free cash flow | -2507.52 | 0.91 | -276,627.37 |
| earnings yield | -0.0 | -0.6 | 99.93 |
| free cash flow yield | -0.0 | -0.58 | 99.93 |
| debt to equity | 0 | 0 | NaN |
| debt to assets | 0 | 0 | NaN |
| net debt to ebitda | 0 | 2.55 | -100.00 |
| current ratio | 6.38 | 3.47 | 83.64 |
| interest coverage | 0 | 0 | NaN |
| income quality | 0.92 | 0.96 | -4.22 |
| dividend yield | 0 | 0 | NaN |
| payout ratio | 0 | 0 | NaN |
| sales general and administrative to revenue | 0 | 0 | NaN |
| research and ddevelopement to revenue | 0 | 0 | NaN |
| intangibles to total assets | 0 | 0 | NaN |
| capex to operating cash flow | 0 | 0 | NaN |
| capex to revenue | 0 | 0 | NaN |
| capex to depreciation | 0 | 0 | NaN |
| stock based compensation to revenue | 0 | 0 | NaN |
| graham number | 0.01 | 24.54 | -99.95 |
| roic | 0 | -0.51 | 100.00 |
| return on tangible assets | -0.26 | -0.35 | 25.45 |
| graham net net | 0.0 | 6.22 | -99.93 |
| working capital | 4945000 | 3769000 | 31.20 |
| tangible asset value | 4946000 | 3773000 | 31.09 |
| net current asset value | 4945000 | 3769000 | 31.20 |
| invested capital | 4946000 | 3770000 | 31.19 |
| average receivables | 0 | 0 | NaN |
| average payables | 259500 | 327500 | -20.76 |
| average inventory | 0 | 0 | NaN |
| days sales outstanding | 0 | 0 | NaN |
| days payables outstanding | 0 | 30150 | -100.00 |
| days of inventory on hand | 0 | 0 | NaN |
| receivables turnover | 0 | 0 | NaN |
| payables turnover | 0 | 0.0 | -100.00 |
| inventory turnover | 0 | 0 | NaN |
| roe | -0.31 | -0.49 | 37.02 |
| capex per share | 0 | 0 | NaN |
ROE: Return on Equity (ROE) increased to -0.31 on 2024-09-30 Q3 from -0.49 on 2024-06-30 Q2, representing a change of 37.02%. However, ROE is <= 5%, suggesting that the company has not been generating high returns for its shareholders.
PE Ratio: Price-to-Earnings (P/E) Ratio decreased to -560.30 on 2024-09-30 Q3 from -0.42 on 2024-06-30 Q2, representing a change of -133938.60%. Indicating a decrease in the relative valuation of the company's stock.
Current Ratio: Current Ratio increased to 6.38 on 2024-09-30 Q3 from 3.47 on 2024-06-30 Q2, representing a change of 83.64%. The current ratio has been increasing, suggesting an increase in the company's short-term liquidity. Since it's above 3, indicating poor management of working capital.
None
| Market Capitalization | Enterprise Value | |
|---|---|---|
| Definition | The total market value of a company's outstanding shares | The total market value of a company, including its debt and other liabilities |
| Calculation | Current share price * Total number of outstanding shares | Market capitalization + Total debt - Cash and cash equivalents |
| Focus | Equity component of a company's value | Total economic value of a company |
| Usefulness | Assesses a company's size and growth potential based on investor sentiment | Provides a more comprehensive valuation that considers both equity and debt |
Analyzing dividends is a crucial aspect of investment evaluation, offering valuable insights into a company's financial health and its commitment to shareholder returns. Dividends represent a portion of a company's profits distributed to its shareholders, providing a steady income stream. We help you analyze dividends based on the indicators mentioned below:
• Investors often assess the average dividend amount, observing trends over time to gauge the company's stability and growth potential. A positive trend in average dividends indicates a consistent and potentially lucrative investment. Additionally, evaluating the trend of dividend increases provides insight into the company's financial strength and management's confidence in future earnings.
• Consistency in paying dividends is a reassuring sign, reflecting a company's reliability and commitment to shareholder value. For investors, dividends not only offer income but also contribute to the overall total return on investment.
• Companies with a history of regular and increasing dividends can attract income-focused investors seeking stable returns, making dividends a critical factor in building a well-rounded investment portfolio.
Interested in the overall sentiment for a particular period? Check out our news sentiment analysis tool.
Sentiment: Positive
Publish Date: 2024-11-14 17:47:00
Marlborough, Massachusetts--(Newsfile Corp. - November 14, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage biotechnology company exploring new pathways towards a cancer-free future by using its INTASYL® siRNA gene silencing technology designed to make the body's immune cells more effective in killing cancer cells today reported its financial results for the quarter ended September 30, 2024 and provided a business update. Recent Corporate Updates The Phase 1b dose escalation clinical trial for our lead product candidate, PH-762, previously received a positive safety recommendation to advance to the next highest dose from the Safety Monitoring Committee (SMC) for the first cohort.
Sentiment: Negative
Publish Date: 2024-11-07 10:00:00
Presenting new clinical data from Phio's on-going Phase 1b trial Marlborough, Massachusetts--(Newsfile Corp. - November 7, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage biotechnology company creating new pathways towards a cancer-free future by using its INTASYL® siRNA gene silencing technology designed to make the body's immune cells more effective in killing cancer cells. Phio announced today that it is presenting clinical data from its on-going Phase 1b clinical trial at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC), which will be held in Houston, TX from November 8-10, 2024.
Sentiment: Negative
Publish Date: 2024-11-01 07:45:00
Registration Link for Presentation and live Q&A to take place, Thursday, November 7 at 12:00 pm EST Marlborough Massachusetts--(Newsfile Corp. - November 1, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage biotechnology company creating new pathways towards a cancer-free future by using its INTASYL® siRNA gene silencing technology designed to make the body's immune cells more effective in killing cancer cells announced today that management will present in the live Virtual Non-Deal Roadshow Series hosted by Renmark Financial Communications Inc. Mr. Robert Bitterman, CEO and Chairman of the Board, Phio Pharmaceuticals will present on Thursday, November 7 at 12:00 pm EST.
Sentiment: Negative
Publish Date: 2024-10-18 13:30:00
Presentation and live Q&A to take place Wednesday, October 23, 2024, at 12 PM EDT Marlborough, Massachusetts--(Newsfile Corp. - October 18, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical stage biotechnology company whose proprietary INTASYL® siRNA gene silencing technology is designed to make immune cells more effective in killing tumor cells, announced today that management will present in the live Virtual Non-Deal Roadshow Series hosted by Renmark Financial Communications Inc. Mr. Robert Bitterman, CEO and Chairman of the Board, Phio Pharmaceuticals will present on Wednesday, October 23, 2024, at 12 PM EDT.
Sentiment: Negative
Publish Date: 2024-10-18 08:00:00
Presentation and live Q&A to take place Wednesday, October 23, 2024, at 12 PM EDT Marlborough, Massachusetts--(Newsfile Corp. - October 18, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical stage biotechnology company whose proprietary INTASYL® siRNA gene silencing technology is designed to make immune cells more effective in killing tumor cells, announced today that management will present in the live Virtual Non-Deal Roadshow Series hosted by Renmark Financial Communications Inc. Mr. Robert Bitterman, CEO and Chairman of the Board, Phio Pharmaceuticals will present on Wednesday, October 23, 2024, at 12 PM EDT.
Sentiment: Negative
Publish Date: 2024-10-16 08:00:00
PH-894: Potent and Specific Silencing of BRD4 in NK Cells Marlborough, Massachusetts--(Newsfile Corp. - October 16, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage biotechnology company creating new pathways towards a cancer-free future by using its INTASYL® siRNA gene silencing technology designed to make the body's immune cells more effective in killing cancer cells. Phio announced today that it is presenting data about its INTASYL compound PH-894 at the American Society of Gene & Cell Therapy's (ASGCT's) 2024 Advancing Gene and Cell Therapies for Cancer conference.
Sentiment: Negative
Publish Date: 2024-10-07 08:00:00
INTASYL compounds also improve the functionality and outcomes of adoptive cell therapies such as NK, TIL and CAR-T Marlborough, Massachusetts--(Newsfile Corp. - October 7, 2024) - Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL® siRNA gene silencing technology is designed to make immune cells more effective in killing tumor cells, today announced that it is presenting data about its proprietary INTASYL platform and INTASYL compounds. INTASYL compounds offer precise targeting by silencing mRNA both intracellularly and extracellularly, significantly enhancing immune responses against cancer.
Sentiment: Negative
Publish Date: 2024-10-02 08:00:00
Presentation and live Q&A to take place Wednesday, October 9, 2024, at 2 PM EDT Marlborough, Massachusetts--(Newsfile Corp. - October 2, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical stage biotechnology company whose proprietary INTASYL® siRNA gene silencing technology is designed to make immune cells more effective in killing tumor cells, announced today that management will present in the live Virtual Non-Deal Roadshow Series hosted by Renmark Financial Communications Inc. Mr. Robert Bitterman, CEO and Chairman of the Board, Phio Pharmaceuticals will present on Wednesday, October 9, 2024, at 2 PM EDT.
Sentiment: Negative
Publish Date: 2024-09-25 08:00:00
--Data will be presented at the conference in October in Montreal Marlborough, Massachusetts--(Newsfile Corp. - September 25, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical stage biotechnology company whose proprietary INTASYL® siRNA gene silencing technology is designed to make immune cells more effective in killing tumor cells, today announced it is presenting data about INTASYL, its patented technology platform at the 20th Annual Oligonucleotide Therapeutics Society (OTS) Meeting. The conference will be held from October 6th-9th in Montreal, bringing together leading experts in oligonucleotide research.
Sentiment: Negative
Publish Date: 2024-09-17 08:00:00
Presentation and live Q&A to take place Tuesday, September 24, 2024, at 12 PM EDT Marlborough, Massachusetts--(Newsfile Corp. - September 17, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical stage biotechnology company whose proprietary INTASYL® siRNA gene silencing technology is designed to make immune cells more effective in killing tumor cells, announced today that management will present in the live Virtual Non-Deal Roadshow Series hosted by Renmark Financial Communications Inc. Mr. Robert Bitterman, CEO and Chairman of the Board, Phio Pharmaceuticals will present on Tuesday, September 24, 2024, at 12 PM EDT.
Sentiment: Positive
Publish Date: 2024-09-16 08:00:00
Phio's INTASYL self-delivering RNAi technology enhances cell potency and yield in Adoptive Cell Therapy Marlborough, Massachusetts--(Newsfile Corp. - September 16, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical stage biotechnology company whose proprietary INTASYL® siRNA gene silencing technology is designed to make immune cells more effective in killing tumor cells, today announced that it is presenting data about its INTASYL technology platform which represents an innovative and flexible solution for adoptive cell therapy providing compounds designed specifically to enhance cell potency and improve overall yield, offering a more effective approach for treating cancer. The data will be presented at the CAR-TCR Summit taking place September 17-20 in Boston, MA.
Sentiment: Negative
Publish Date: 2024-09-09 07:00:00
Conference to be held in New York City September 9-11th Marlborough, Massachusetts--(Newsfile Corp. - September 9, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical stage biotechnology company whose proprietary INTASYL® siRNA gene silencing technology is designed to make immune cells more effective in killing tumor cells, today announced that its President and CEO, Robert Bitterman, will be attending and presenting at the H.C. Wainwright 26th Annual Global Investment Conference being held September 9-11, 2024 at the Lotte New York Palace Hotel in New York City, NY.
Sentiment: Negative
Publish Date: 2024-08-29 08:30:00
Presentation and live Q&A to take place Thursday, September 5, 2024, at 12 PM EDT Marlborough, Massachusetts--(Newsfile Corp. - August 29, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical stage biotechnology company whose proprietary INTASYL® siRNA gene silencing technology is designed to make immune cells more effective in killing tumor cells, announced today that management will present in the live Virtual Non-Deal Roadshow Series hosted by Renmark Financial Communications Inc. Mr. Robert Bitterman, CEO and Chairman of the Board, Phio Pharmaceuticals will present on Thursday, September 5, 2024, at 12 PM EDT.
* The sentiment analysis presented is generated through an algorithm and may be subject to inaccuracies. Users are advised to corroborate key information and employ further analytical methods prior to making critical decisions.
Get instant AI-powered professional insights:
💡Generate AI Technical Analysis ReportUnderstand the chart below:
Interpret Technical Indicators
| Indicator | Bullish | Bearish |
|---|---|---|
| Price and EMA ⓘ | Price crosses above EMA | Price crosses below EMA |
| Short-Term vs Long-Term EMA ⓘ | Short EMA crosses above Long EMA | Short EMA crosses below Long EMA |
| Volume ⓘ | Increasing volume during price uptrend | Increasing volume during price downtrend |
| MACD ⓘ | MACD crosses above Signal Line | MACD crosses below Signal Line |
| RSI ⓘ | RSI is below 30 (oversold) and starts to rise above 30 | RSI is above 70 (overbought) and starts to decline below 70 |
| Candlestick Patterns ⓘ | Bullish candlestick patterns | Bearish candlestick patterns |
Copyright © 2024 Sirius Investors
All rights reserved
